
Nanosonics Ltd (ASX: NAN) shares have fallen almost 30% over the past year, but according to the team at RBC Capital Markets, they could be primed for a recovery.
The broking house has just released a new research report on the company and has assigned it an outperform rating and a bullish share price target, which I’ll get to shortly.
First, let’s look at the company’s most recent news â its FY26 financial results and the announcement of a share buyback.
Steady year, with core business performing well
Nanosonics’ main revenue-generating business at the moment is its Trophon division, which placed 4230 new units during the year, up 9%.
The company’s revenue was up 3% to $203.9 million, while EBIT was $16 million, down 10%.
If the Trophon division is looked at on a stand-alone basis, its EBIT would be $50.6 million.
The company had no debt and cash on hand of $155.2 million at the end of the year, having completed a $20 million buyback.
Nanosonics also announced a new, $40 million buyback for FY27.
Chief Executive Officer Michael Kavanagh said:
Nanosonics is entering a defining period of growth. FY26 demonstrated the strength of the business we have built: a proven Trophon franchise, disciplined financial execution and in FY27 we will progress the CORIS System from CMR to commercialisation. Trophon remains the economic engine for Nanosonics and an important foundation for future value creation. We delivered 6% revenue growth and 21% EBIT growth in constant currency. We achieved our strongest annual placement volume in three years, record upgrades in North America and expanded the cumulative installed base. We also launched trophon3 and trophon2 Plus, and saw accelerating adoption of these next generation technologies in the second half.
Mr Kavanagh said the CORIS system had the potential to establish a new standard of care in endoscope reprocessing and build a recurring revenue business over time.
He said the company planned to launch CORIS across the UK, Ireland, and Australia in the first half of FY27, with the US launch to follow.
Shares looking cheap, broker says
RBC Capital Markets said in their research note that the current Nanosonics share price “is implying an overly bearish scenario”.
They added:
NAN’s Trophon business improved its profitability with EBIT increasing from $47m in FY25 to $50m in FY26. While we expect Trophon capital sales will be negatively impacted by tariffs in higher freight costs, we expect absolute profitability to continue increasing in FY27 and are forecasting Trophon only EBIT of $54m (+8%). We value the Trophon only business at $3.55/share.
RBC has revised its forecasts to assume CORIS hits breakeven over the horizon period.
Its price target for Nanosonics shares has increased from $3 to $3.75, compared with a share price of $2.88 at the time of writing.
Nanosonics is valued at $836.9 million.
The post This ASX biotech could jump more than 30%, one broker says appeared first on The Motley Fool Australia.
Should you invest $1,000 in Nanosonics right now?
Before you buy Nanosonics shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Nanosonics wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded
- 5 ASX shares downgraded by Morgans post-results
- Nanosonics posts FY26 revenue growth and prepares to launch CORIS
Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics. The Motley Fool Australia has recommended Nanosonics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

